Cellectar Biosciences ( (CLRB) ) just unveiled an announcement.
On March 12, 2025, Cellectar Biosciences’ board approved amendments to the employment agreements of its CEO and COO, enhancing their severance benefits in the event of a change in control. Additionally, on March 11, 2025, the board adopted new by-laws to align with Delaware law, revising stockholder nomination procedures and reducing the quorum requirement for meetings.
More about Cellectar Biosciences
Cellectar Biosciences, Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for cancer treatment.
YTD Price Performance: -2.78%
Average Trading Volume: 2,032,924
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $14.54M
For an in-depth examination of CLRB stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com